Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 86Lung Neoplasms 64Carcinoma, Non-Small-Cell Lung 50Neoplasm Metastasis 48Breast Neoplasms 48Glioma 41Glioblastoma 38Pancreatic Neoplasms 35Multiple Myeloma 35Brain Neoplasms 34Carcinoma, Renal Cell 33Lymphoma, Large B-Cell, Diffuse 29Melanoma 28Urinary Bladder Neoplasms 27Colorectal Neoplasms 27Squamous Cell Carcinoma of Head and Neck 25Ovarian Neoplasms 24Triple Negative Breast Neoplasms 21Oropharyngeal Neoplasms 21Carcinoma, Hepatocellular 21Lymphoma 20Mouth Neoplasms 18Lymphoma, Follicular 18Sarcoma 17Fallopian Tube Neoplasms 16Carcinoma, Transitional Cell 16Carcinoma 16Laryngeal Neoplasms 15Astrocytoma 15Lymphoma, Mantle-Cell 14

Interventions

trastuzumab biosimilar HLX02 1exemestane 1X-Rays 1Trastuzumab 1Taxes 1TVB-2640 1Specimen Handling 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1Letrozole 1Fulvestrant 1Disulfides 1CT-P6 1Biopsy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Breast Carcinoma × Magnetic Resonance Spectroscopy × 1 year × Clear all
NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
17 enrolled 10 charts
Breast

Advanced Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡